Advanced Medical Solutions Grp PLC Notice of Interim Results (8553I)

TIDMAMS

RNS Number : 8553I

Advanced Medical Solutions Grp PLC

10 August 2023

10 August 2023

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Notice of Interim Results

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2023 on Wednesday 20 September 2023.

A briefing for analysts will be held at 10am BST on the day of the results. For further information, please contact [e-mail] .

- End -

For further information, please contact:

 
 Advanced Medical Solutions Group plc         Tel: [phone] 
                                                         545508 
 Chris Meredith, Chief Executive Officer 
  Eddie Johnson, Chief Financial Officer 
  Michael King, Investor Relations 
 
 Consilium Strategic Communications        Tel: [phone] 
                                                           5700 
 Matthew Neal / Lucy Featherstone 
 
 Investec Bank PLC (NOMAD & Broker)        Tel: [phone] 
                                                           5970 
 Gary Clarence / David Anderson 
 HSBC Bank PLC (Broker)                    Tel: [phone] 
                                                           8888 
 Sam McLennan / Joe Weaving / Stephanie 
  Cornish 
 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand(R), RESORBA(R), LiquiBandFix8(R) and Seal-G(R). AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal(R) brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORQKLFBXVLEBBF

(END) Dow Jones Newswires

August 10, 2023 02:00 ET (06:00 GMT)